The short interest data are out for the most recent settlement date, February 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big…
The top analyst upgrades, downgrades and other research calls from Wednesday include Celgene, Chevron, Exxon Mobil, Frontier Communications, JPMorgan, Lam Research, Procter & Gamble, Square and Workday.
Cancer immunotherapy approaches have attracted the attention of Big Pharma in the past. New technology from Stanford University probably will be no exception if Phase 1 results are positive.
These were 13 stock buyback and dividend hike announcements from the week of February 16 that were simply too large to be ignored.
With indiscriminate selling absolutely punishing some of the top large cap biotech stocks, one analyst says now is the time to buy.
The the top analyst upgrades, downgrades and other research calls from Tuesday include ADT, CBOE, Celgene, JPMorgan, 3M, NetApp, Total, Tyson Foods and Weatherford.
The January 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
24/7 Wall St. has included a calendar of a some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February.
The January 12 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Juno Therapeutics saw its shares take off early on Monday after it was announced that Celgene would be acquiring it.
Chris Lange Juno Therapeutics saw its shares skyrocket early on Wednesday after reports that Celgene was in talks to acquire the company.
Chris Lange The December 29 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and good, that it believes will play a big role in the coming…
Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock moves. Some stocks have the potential to double or even crater, should…
Jefferies has put together a list of 10 biotech companies that could have developments coming up in the next two weeks to start the year.
